You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-948-ESGO Neoadjuvant Chemotherapy (NACT) and Interval Debulking Surgery (IDS) in a Group of Patients with Advanced Stage Epithelial Ovarian Cancer, Unsuitable for Upfront Surgery

Article metrics

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-948-ESGO Neoadjuvant Chemotherapy (NACT) and Interval Debulking Surgery (IDS) in a Group of Patients with Advanced Stage Epithelial Ovarian Cancer, Unsuitable for Upfront Surgery
Free

 

Online download statistics by month:

Online download statistics by month: October 2022 to October 2024

AbstractFullPdf
Oct 20221001
Nov 20222202
Dec 20225606
Jan 20232002
Feb 2023906
Mar 2023601
Apr 20232201
May 2023600
Jun 2023300
Jul 2023806
Aug 20231606
Sep 2023406
Oct 2023600
Nov 20231402
Dec 20232303
Jan 2024801
Feb 20241001
Mar 20241002
Apr 20241000
May 20241004
Jun 20241603
Jul 2024605
Aug 2024504
Sep 2024802
Oct 2024200
Total310064